» Articles » PMID: 39407743

Microscopic Colitis: An Underestimated Disease of Growing Importance

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Oct 16
PMID 39407743
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this paper is to raise awareness of MC as a clinically significant condition and to highlight its under-recognition, risk factors, diagnosis, management, and complications. This paper underlines the diagnostic and therapeutic challenges associated with the often nonspecific symptoms of MC. In order to create this article, we reviewed available articles found in the PubMed database and searched for articles using the Google Scholar platform. Microscopic colitis (MC) is a chronic inflammatory bowel disease, classified into three types: lymphocytic, collagenous, and unspecified. The average age of onset of MC is around 62-65 years and the disease is more common in women than men (nine times more common). The main symptom of MC is watery diarrhoea without blood, other symptoms include defecatory urgency, faecal incontinence, abdominal pain, nocturnal bowel movements, and weight loss. Once considered a rare disease, MC is now being diagnosed with increasing frequency, but diagnosis remains difficult. To date, a number of causative factors for MC have been identified, including smoking, alcohol consumption, medications (including NSAIDs, PPIs, SSRIs, and ICPIs), genetic factors, autoimmune diseases, bile acid malabsorption, obesity, appendicitis, and intestinal dysbiosis. It may be difficult to recognize and should be differentiated from inflammatory bowel diseases (Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), coeliac disease, infectious bowel disease, and others. Diagnosis involves biopsy at colonoscopy and histopathological evaluation of the samples. Treatment consists of budesonide oral (the gold standard) or enema. Alternatives include bile acid sequestrants (cholestyramine, colesevelam, and colestipol), biologics (infliximab, adalimumab, and vedolizumab), thiopurines, methotrexate, and rarely, surgery.

References
1.
Bislenghi G, Ferrante M, De Hertogh G, Sucameli F, Wolthuis A, Sabino J . Proctocolectomy and ileal pouch-anal anastomosis for the treatment of collagenous colitis. Clin J Gastroenterol. 2022; 15(3):586-591. DOI: 10.1007/s12328-022-01611-x. View

2.
Weimers P, Ankersen D, Lophaven S, Bonderup O, Munch A, Lokkegaard E . Incidence and Prevalence of Microscopic Colitis Between 2001 and 2016: A Danish Nationwide Cohort Study. J Crohns Colitis. 2020; 14(12):1717-1723. DOI: 10.1093/ecco-jcc/jjaa108. View

3.
Besendorf L, Muller T, Geppert C, Schneider I, Muhl L, Atreya I . Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis. Therap Adv Gastroenterol. 2022; 15:17562848221098899. PMC: 9244938. DOI: 10.1177/17562848221098899. View

4.
Cotter T, Binder M, Loftus Jr E, Abboud R, McNally M, Smyrk T . Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. Gut. 2016; 67(3):441-446. DOI: 10.1136/gutjnl-2016-313051. View

5.
Khalili H, Bergman D, Roelstraete B, Burke K, Sachs M, Olen O . Mortality of Patients With Microscopic Colitis in Sweden. Clin Gastroenterol Hepatol. 2019; 18(11):2491-2499.e3. DOI: 10.1016/j.cgh.2019.12.012. View